Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.This transaction
This business integrationCounterpartyAmanat Acquisition Corp
Disclosing companyTMS Co.,Ltd.
Execution Date / Effective DateFirst half of 2027 (planned)
Consideration and expenses
Type of ConsiderationShares (common shares of the combined company; warrants may be received in lieu of all or part of the shares)
Impact on Business Performance
No material impact on the progress of the ORION trial from the business combination is currently expected. Whether Corxel Group will distribute shares and warrants to our company, as well as the timing, amount and other details, has not been determined.
Procedures and assumptions
Conditions Precedent to ExecutionShareholder approval by the relevant parties, NASDAQ listing approval and other prescribed conditions
Management structure after acquisitionFollowing completion of the business combination, Corxel US's business will be transferred to a wholly owned subsidiary of AMAN, and AMAN is expected to change its name and become the post-combination listed company. Employee terms: not disclosed
| Item | Details |
|---|---|
| Transaction name | This business integration |
| Counterparty name | Amanat Acquisition Corp |
| Name of the Subject Company | Corxel Pharmaceuticals, Inc. |
| Type of Consideration | Shares (common shares of the combined company; warrants may be received in lieu of all or part of the shares) |
| Impact on Business Performance | No material impact on the progress of the ORION trial from the business combination is currently expected. Whether Corxel Group will distribute shares and warrants to our company, as well as the timing, amount and other details, has not been determined. |
| Execution Date / Effective Date | First half of 2027 (planned) |
| Conditions Precedent to Execution | Shareholder approval by the relevant parties, NASDAQ listing approval and other prescribed conditions |
| Management structure after acquisition | Following completion of the business combination, Corxel US's business will be transferred to a wholly owned subsidiary of AMAN, and AMAN is expected to change its name and become the post-combination listed company. Employee terms: not disclosed |
Items this document does not state (24)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose and rationale for the business combination are not stated in the body of the document.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.